Physician profile
David D Gross
NPI 1538130398
$1,160.18
in general payments reported to CMS, 2019-2025
19 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.08 · 2020: $24.53 · 2021: $161 · 2022: $77.97 · 2023: $279 · 2024: $430 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.89 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $151.99 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $135.12 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $120.93 | 2021-2024 | |
| Exact Sciences Corporation | $109.24 | 2023-2024 | Cologuard Collection Kit |
| Leo Pharma INC. | $87.85 | 2025 | Anzupgo |
| Lilly USA, LLC | $63.56 | 2021-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $41.09 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $32.41 | 2024 | Repatha, Otezla |
| Sun Pharmaceutical Industries INC. | $31.80 | 2025 | |
| Almatica Pharma LLC | $29.41 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Merck Sharp & Dohme LLC | $25.26 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Sanofi Pasteur INC. | $22.69 | 2019-2020 | |
| Philips North America LLC | $15.60 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.15 | 2020 | |
| Glaxosmithkline, LLC. | $12.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.